Pharmaceuticals, Biotechnology and Life Sciences
Teva Pharmaceutical Industries on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline’s best-selling Advair.
Patients with eosinophilic inflammation that were treated with GSK’s mepolizumab Nucala as addition to the standard care, reached improvements in health and lung function compared to patients treated with placebo added to the standard care.
Teva’s two asthma treatments for patients older than 12 has been approved by the US Food and Drug Administration (FDA).
AstraZeneca’s Symbicort Inhalation Aerosol is going to be available for 6-12 years old children with asthma in the US
Vectura Group is moving on with researching and testing its VR647, a drug/device combination to treat asthma in children for the US market.
GlaxoSmithKline and Innoviva have started a phase III study to compare certain triple combination asthma therapy with a double combination…
Verona Pharma has completed patient enrolment for the Phase IIa dose-finding study of RPL554 in asthma and the Phase IIa combination study of RPL554 in chronic obstructive pulmonary disease (COPD), in which the drug is being administered in addition to standard of care bronchodilators.